Advisory Committee

Joshua Brody, MD, is the director of the Lymphoma Immunotherapy Program at the Mount Sinai Health System & Tisch Cancer Institute and a faculty member of the Icahn Genomics Institute His clinical focus includes lymphoma, adult non-Hodgkin’s lymphoma, Hodgkin’s disease, Hodgkin’s lymphoma, mantle cell lymphoma, primary central nervous system lymphoma, and leukemia.

Dr. Brody is a faculty member of the Icahn Genomics Institute and a member of the Society for the Immunotherapy of Cancer and the Alliance for Clinical Trials in Oncology. He has developed a clinical program as well as a translational cancer immunotherapy lab that investigates basic and applied tumor immunology for the development of novel therapies, particularly for lymphomas, breast cancer, and head/neck cancer, with results published in journals including Nature Medicine and Cancer Discovery. He has pioneered a therapeutic vaccine approach—in situ vaccination—that induces anti-tumor immunity at the tumor site and can cause regression of tumors throughout the body. He has also developed a way to increase the power of immunotherapy drugs against treatment-resistant lymphomas by combining them with stem cell transplantation. Recently, his group discovered a novel approach to improve immunotherapies by preventing a common escape mechanism that tumors use to evade CAR-T and bispecific antibody therapies.

Dr. Brody is board certified in internal medicine and completed his fellowship in medical oncology at Stanford University. He completed his residency in internal medicine at Yale New Haven Hospital and earned his medical degree at the State University at Stony Brook.

Elizabeth Lihua Budde, MD, PhD, is an associate professor in the Division of Lymphoma, Department of Hematologic Oncology & Hematopoietic Cell Transplantation and executive director of the Enterprise Immune Effector Cell Program at City of Hope National Medical Center in Duarte, California. She specializes in the treatment and research of blood malignancies. Her scholarly focus is on immunotherapies for patients with leukemia and lymphoma, and she has clinical expertise in lymphoma, leukemia, and bone marrow and stem cell transplant.

Dr. Budde is the recipient of numerous Clinical Investigator awards and her articles have appeared in Nature Medicine, The Lancet Oncology, Journal of Clinical Oncology, Blood, Journal of Hematology & Oncology, and Clinical Cancer Research. As the lead investigator for several translational research studies, Dr. Budde manages an array of clinical trials and has been invited to speak at various national and international conferences. She serves on the NCCN Guidelines Panel for B Cell Lymphoma as well as Management of Immunotherapy Related Toxicities Panel and serves on several consortiums and associations, including the Association of American Cancer Institutes CAR T Working Group, Mantle Cell Lymphoma Consortium at the Lymphoma Research Foundation, American Society of Hematology, and American Society of Clinical Oncology.

Dr. Budde is board certified in medical oncology and internal medicine. She completed a fellowship at the University of Washington Fred Hutchinson Cancer Research Center and her residency at Washington University School of Medicine. She earned her medical degree and her PhD at Duke University and earned her bachelor’s degree from Tongji Medical University in China.

Srinivas Devarakonda, MD, is an associate professor in the Division of Hematology at The Ohio State University Comprehensive Cancer Center – The James in Columbus, Ohio and a board-certified hematologist/oncologist. His clinical expertise includes plasma cell cancers, multiple myeloma, and bone transplantation and specializes in the treatment of plasma cell dyscrasias, amyloidosis, and Waldenstrom macroglobulinemia.

In addition to his clinical work, Dr. Devarakonda trains students and trainees in his current role as associate professor at The Ohio State University. He served as associate professor in the Department of Internal Medicine and associate program director for the Hematology/Oncology Fellowship Program at Louisiana State University Health Sciences Center. He is a member of several professional organizations, including the American Society of Clinical Oncology, the American Society of Hematology, and the American College of Physicians.

Dr. Devarakonda completed a hematology/oncology fellowship at Louisiana State University Health Sciences Center, where he was also chief fellow. Dr. Devarakonda completed his internal medicine residency training at Guthrie Robert Packer Hospital in Pennsylvania. He obtained his medical degree at Osmania Medical College in India.

Jean Koff, MD, MSc, is an associate professor in the Department of Hematology and Medical Oncology and director of the lymphoma program’s translational research team at the Winship Cancer Institute of Emory University. Her clinical expertise in lymphoma is complemented by her research characterizing the immunologic and genetic factors that contribute to poor outcomes in lymphoma patient populations who are underrepresented in most studies, such as African Americans and organ transplant recipients.

Dr. Koff serves as an investigator on several team science projects involving multi-institutional cohorts of lymphoma patients with integrated analyses of clinical and molecular data, including the Lymphoma Epidemiology of Outcomes cohort study. She is the 2024 chair of the Scientific Committee on Lymphoid Neoplasia for the American Society of Hematology. Dr. Koff’s work has been funded by the Lymphoma Research Foundation, the American Association for Cancer Research, the American Cancer Society, and the National Institutes of Health.

Dr. Koff received her medical degree from Emory University School of Medicine in Atlanta, Georgia. Her postgraduate medical education included a J. Willis Hurst Internal Medicine Residency at Emory University and a fellowship in hematology and medical oncology at Winship Cancer Institute, where she was chief fellow in her final year.

Cassie Martin, MMS, PA-C, is a board-certified physician assistant at Penn Medicine Lancaster General Health’s Ann B. Barshinger Cancer Institute in Lancaster, Pennsylvania. She has a range of clinical expertise across several disease types, including lung, colon, gastrointestinal, breast, and hematologic cancers and benign hematology. Her clinical interests include immunotherapy, CAR-T therapy, BiTE therapy, adjuvant chemotherapy, and symptom management.

Martin earned a master’s degree in physician assistant studies from Salus University and her bachelor’s degree from West Chester University of Pennsylvania.

Amitkumar Mehta, MD, is an associate professor and associate scientist at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham (UAB). He is the director of the Lymphoma and CAR-T program at UAB. Dr. Mehta is a board-certified hematologist and oncologist with a special interest in lymphomas, including B and T-cell lymphoma, cutaneous T-cell lymphoma, and immune effector cell therapy. He is also a clinical investigator with a special interest in developing non-chemotherapy approaches to treating lymphoma, including immunotherapy, CAR-T therapy, immune-modulating therapy, and targeted therapy.

Dr. Mehta is a principal investigator of innovative clinical trials for the treatment of lymphoma at UAB. He is also involved in lymphoma-related research, which includes genomic and proteomic (gene- and protein-related) studies in various kinds of lymphomas. As a clinical investigator, he is part of many clinical trials as principal investigator or sub-investigator. Dr. Mehta seeks to develop targeted and immunologic therapies in lymphoma with fewer toxicities and more effectiveness.

Dr. Mehta completed a fellowship at the University of Alabama at Birmingham Hospital and his residency at George Washington University Hospital. He earned his medical degree from Baroda Medical College in Vadodara, India.

Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, is the clinical oncology pharmacy manager and a practicing hematology clinical pharmacist at Atrium Health Levine Cancer in Charlotte, North Carolina. Dr. Moore’s clinical interests include lymphoma, multiple myeloma, chronic leukemias, immune thrombocytopenic purpura, and thrombotic microangiopathies as well as pharmacovigilance, professional writing, and research.

Dr. Moore is a member of the American College of Clinical Pharmacy (ACCP), the American Society of Health-System Pharmacists (ASHP), the Hematology/Oncology Pharmacy Association, and the Advanced Practitioner Society for Hematology and Oncology. He is also a graduate of the ASHP Foundation Pharmacy Leadership Academy and was named a 40 Under 40 in Cancer Award recipient by the National Community Oncology Dispensing Association and Swim Across America. He is also recognized as a fellow of ACCP.

Dr. Moore earned his pharmacy degree from Massachusetts College of Pharmacy and Health Sciences. He completed his residency at Steward St. Elizabeth’s Medical Center in Boston, Massachusetts.

Angie Santiago, BBA, CRCS, FACCC, is a senior business manager for medical oncology at the Sidney Kimmel Cancer Center at the Thomas Jefferson University Health System. She created and implemented the Oncology Patient Assistance Program, which the health system uses to help patients acquire supplemental financial coverage that exceeds what the hospital’s business office has traditionally provided.

Santiago has worked in healthcare for more than two decades within patient access, revenue cycle, and financial counseling. She is a graduate of the Association of Cancer Care Centers Financial Advocacy Network boot camp and currently services as chair for the network’s Advisory Committee. Santiago has also presented on financial toxicity and related topics at patient navigators’ networking meetings.

Bradley Wuthrich, PharmD, is a clinical pharmacist in oncology at Munson Healthcare’s Cowell Family Cancer Center in Traverse City, Michigan. Dr. Wuthrich’s clinical interests include hematologic malignancies, and he has helped bring BiTE therapy to the community setting in Northwest Michigan.

Dr. Wuthrich worked in critical care/emergency room pharmacy services before transitioning to inpatient and outpatient oncology. In the community setting, Dr. Wuthrich works closely with pharmacy colleagues, medical oncologists, and inpatient staff to develop toxicity management protocols and provide nurse and physician education. He also precepts pharmacy students and residents.

Dr. Wuthrich is a 2020 graduate of the Doctor of Pharmacy program at Purdue University and a 2021 graduate of Munson Medical Center’s Post-Graduate Year 1 Pharmacy Residency.